Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
2seventy bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A STATE STREET CORP reports a 2.1% stake in EXIT FILING 2SEVENTY BIO INC
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress Abecma generated $115 million U.S. commercial revenue in 2Q 2023, supporting lower end of U.S. revenue guidance of $470-570 million"
07/27/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure  Interactive Data
05/19/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2 3 4 8",
"Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed"
05/17/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio bbT369, a dual-targeted and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models"
05/01/2023 SC 13G CITADEL ADVISORS LLC reports a 5.2% stake in 2seventy bio, Inc.
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/01/2023 8-K Other Events  Interactive Data
Docs: "2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program 2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023"
04/27/2023 8-K Quarterly results
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/17/2023 8-K Quarterly results
03/17/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress Abecma generated $94M U.S. commercial revenue in 4Q 2022, $297M in FY 2022&#59; anticipate $470-$570M U.S. revenue in 2023"
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors"
03/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "with the Securities and Exchange Commission in the"
03/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Item 1A. Risk Factors"
02/23/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
02/14/2023 SC 13G BAKER BROS. ADVISORS LP reports a 5.4% stake in 2seventy bio, Inc.
02/14/2023 SC 13G/A EcoR1 Capital, LLC reports a 3% stake in 2seventy bio, Inc.
02/10/2023 8-K Quarterly results
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 6.3% stake in 2seventy bio Inc.
02/08/2023 SC 13G/A STATE STREET CORP reports a 6.2% stake in AMENDED FILING 2SEVENTY BIO INC
02/06/2023 8-K Quarterly results
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/02/2023 8-K Quarterly results
01/09/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "with the Securities and Exchange Commission in the",
"2seventy bio Provides Company Outlook for 2023 Anticipate $470-$570M topline U.S. revenue Abecma in 2023, shared equally with Bristol Myers Squibb"
01/06/2023 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy